OM-301

About Oncolyze

Oncolyze is an early-stage biotech with a disruptive approach to oncology, leveraging a simple mechanism of action where its lead fusion peptide, OM-301, binds to cancer cells and physically 'pops' them by lysing the cell membrane. The company is strategically focused on Acute Myelogenous Leukemia (AML), an area of high unmet need with poor survival rates, where preclinical data suggests potential efficacy against leukemic stem cells. Backed by a seasoned leadership team and a distinguished scientific advisory board, Oncolyze is positioning itself to advance its lead candidate through development, with the long-term goal of expanding the platform to other hematologic and solid cancers.

Therapeutic Areas